Resveratrol, MicroRNAs, Inflammation, and Cancer

Tili, Esmerina; Michaille, Jean-Jacques

doi:https://doi.org/10.4061/2011/102431

Journal of Nucleic Acids

On this page

Abstract Conclusions References Copyright Related Articles

Special Issue

Using Chemical Approaches to Understand RNA Structure and Function in Biology

View this Special Issue

Review Article | Open Access

Volume 2011 | Article ID 102431 | https://doi.org/10.4061/2011/102431

Resveratrol, MicroRNAs, Inflammation, and Cancer

Esmerina Tili¹and Jean-Jacques Michaille^1,2

Academic Editor: Dmitry A. Stetsenko

Received20 Oct 2010

Revised15 Jun 2011

Accepted22 Jun 2011

Published10 Aug 2011

Abstract

MicroRNAs are short noncoding RNAs that regulate the expression of many target genes posttranscriptionally and are thus implicated in a wide array of cellular and developmental processes. The expression of miR-155 or miR-21 is upregulated during the course of the inflammatory response, but these microRNAs are also considered oncogenes due to their upregulation of expression in several types of tumors. Furthermore, it is now well established that inflammation is associated with the induction or the aggravation of nearly 25% of cancers. Therefore, the above microRNAs are thought to link inflammation and cancer. Recently, resveratrol (trans-3,4′,5-trihydroxystilbene), a natural polyphenol with antioxidant, anti-inflammatory, and anticancer properties, currently at the stage of preclinical studies for human cancer prevention, has been shown to induce the expression of miR-663, a tumor-suppressor and anti-inflammatory microRNA, while downregulating miR-155 and miR-21. In this paper we will discuss how the use of resveratrol in therapeutics may benefit from the preanalyses on the status of expression of miR-155 or miR-21 as well as of TGFβ1. In addition, we will discuss how resveratrol activity might possibly be enhanced by simultaneously manipulating the levels of its key target microRNAs, such as miR-663.

1. Inflammation and Cancer

Inflammation represents a complex, nonspecific immune response of the body to pathogens, damaged cells, tissue injury, allergens, toxic compounds, or irritant molecules [1]. While it is normally self-contained, it may become permanent and chronic. It may also escape the original tissue and spread via the circulatory and/or the lymphatic system to other parts of the body, producing a systemic inflammatory response syndrome such as sepsis in case of an infection. Chronic inflammation is associated with a simultaneous destruction and healing of the tissue from the inflammatory process and has been linked to a number of pathologies, including cancer, chronic asthma, rheumatoid arthritis, multiple sclerosis, inflammatory bowel diseases, and psoriasis, as well as several types of neurological disorders. The inflammatory response is coordinated by a large range of mediators that form complex regulatory networks [1]. The recruitment of leukocytes in the peripheral tissues is the hallmark of inflammation. It is mediated by several types of chemokines [1–3], which act through their receptors located at the surface of the cytoplasmic membrane of leukocytes. The production of chemokines is induced by inflammatory stimuli such as bacterial lipopolysaccharide (LPS), interleukin (IL)-1, or tumor necrosis factor (TNF). In addition, these chemokines have a clear role in angiogenesis and wound repair [4]. Finely tuned molecular mechanisms exist that ensure that the immune response required for the defense of the body has a limited duration and does not pass a certain maximum activation level, thus avoiding that, it becomes harmful to the organism. It is well acknowledged that unresolved immune response results in inflammation.

Epidemiological studies suggest that as many as 25% of all cancers may be due to chronic inflammation [5–7]. The connection between inflammation and cancer consists of an extrinsic pathway, driven by inflammatory conditions that increase cancer risk, and an intrinsic pathway, driven by genetic alterations that cause inflammation and neoplasia [6]. Inflammatory mediators released by cancer-related inflammation induce genetic instability, leading to the accumulation of random genetic alterations in cancer cells [7]. The activation of Toll-like receptors (TLRs), a group of pattern recognition receptors functioning as sensors of pathogens and tissue damages, leads to the nuclear translocation of NF-κB and the production of cytokines such as TNF, IL-1α, IL-1β, IL-6, and IL-8. However, TLR activation has been shown to accelerate the growth of adoptively transferred tumors [8–11]. Accordingly, the stimulation of TLRs leads to increased survival and proliferation of several cell lines [12, 13], and the intratumoral injection of Listeria monocytogenes induces TLR2 signaling in tumor cells, thus promoting their growth [14]. TLR signaling also enhances tumor cell invasion and metastasis by regulating metalloproteinases and integrins [15]. Chemokines also affect several tumor progression pathways, such as leukocyte recruitment and function, cellular proliferation, survival, or senescence, as well as invasion and metastasis and are the targets of a number of anticancer agents [5].

Tumor microenvironment contains various inflammatory cell types infiltrating the tumor area in response to inflammatory stimuli, such as macrophages, neutrophils, and mast cells [16, 17]. Tumor-associated macrophages (TAMs) are thought to play key roles in the production of various growth factors, angiogenic factors, proteinases, chemokines, and cytokines, through crosstalks with cancer cells and other tumor stromal cells [18–20]. Factors secreted by TAMs stimulate cell migration/motility, proliferation, survival, angiogenesis, and metastasis, resulting in a dynamic environment that favors the progression of cancer, thus affecting the clinical outcome of malignant tumors. TAMs have thus been described as “obligate partners for tumor-cell migration, invasion and metastasis” [21, 22]. Namely, in a genetic model of breast cancer in macrophage-deficient mice, the tumors developed normally but were unable to form pulmonary metastases in the absence of macrophages [23]. As tumor metastasis is responsible for approximately 90% of all cancer-related deaths, a better understanding of inflammation regulatory mechanisms may potentially allow to optimize the use of anticancer drugs that lower tumor-specific inflammatory response [18].

Finally, the transforming growth factor β (TGFβ) regulates the immune response as well as the effects of the immune system on tumor progression or regression in vivo [24]. TGFβ has been shown to suppress the antitumor activity of T cells, natural killer (NK) cells, neutrophils, monocytes, and macrophages, which together are able to promote or repress tumor progression depending on the cellular context [25–27]. Importantly, TGFβ1, the most abundant and ubiquitously expressed isoform of TGFβ, is usually considered a tumor-suppressor, due to its cytostatic activity in epithelia. However, on advanced stages of tumors, TGFβ1 behaves as a tumor promoter, due to its capability to enhance angiogenesis, epithelial-to-mesenchymal transition, cell motility, and metastasis [28–30].

2. MicroRNAs and Inflammation

MicroRNAs (miRNAs) are short noncoding RNAs which regulate the translation and/or degradation of target messenger RNAs [31–33]. They have been implicated in the regulation of a number of fundamental processes, including muscle, cardiac, neural, and lymphocyte development, or the regulation of both the innate and adaptative immune responses [34, 35]. miRNAs originate from primary transcripts (pri-miRNAs) converted in the nucleus into precursor miRNAs (pre-miRNAs) by the RNase III Drosha, associated with DGCR8 to form the small microprocessor complex [36]. Pre-miRNAs are then exported in the cytoplasm where the miRNA hairpin is cleaved by the RNase III Dicer within the RISC loading complex. The guide strand, which corresponds to the mature miRNA, is then incorporated into the RISC complex [36]. miRNAs and their transcriptional regulators usually form autoregulatory loops aimed at controlling their respective levels [37]. miRNAs participate in many gene regulatory networks whose molecular malfunctions are associated with major pathologies such as cancer [34] or auto-mmune diseases [38–40].

Several miRNAs have been implicated in both inflammation and cancer [38–41]. The most prominent are miR-155, miR-21, and miR-125b. Thus the expression of miR-155 is strongly elevated in several human leukemias and lymphomas ([40] and references therein). Transgenic mice with B cells overexpressing miR-155 develop B-cell leukemia, and a sustained expression of miR-155 in hematopoietic stem cells causes a myeloproliferative disorder [40]. On the other side, miR-155 has been implicated in the regulation of myelopoiesis and erythropoiesis, Th1 differentiation, B-cell maturation, IgG1 production, somatic hypermutations, gene conversion, class switch recombination, and B- and T-cell homeostasis as well as in the regulation of the innate immune response [40]. Thus, miR-155 levels increase following LPS treatment of Raw-264 macrophages, and miR-155 transgenic mice show enhanced sensibility to LPS-induced endotoxin shock [42]. In contrast, miR-155-knock-out mice are unable to mount a proper T-cell or B-cell immune response [40]. The expression of another miRNA, miR-125b, was repressed within 1 hour of LPS challenge in Raw-264 cells [42]. In topic eczema, miR-125b expression was reduced in regions of the skin that were inflamed, while that of miR-21 was enhanced [43]. Similarly, miR-21 expression was increased by inflammation due to ulcerative colitis [44] and also by IL-13 and by specific antigens in OVA- and Aspergillus fumigatus antigens-induced asthma models [45]. The expression of miR-21 changes dynamically during antigen-induced T-cell differentiation, with the highest levels of expression in the effector T cell [46]. MiR-21 induction upon T-cell receptor (TCR) stimulation is believed to be involved in a negative feedback loop regulating TCR signaling [46]. MiR-663 has drown recent attention due to its role not only as an anti-inflammatory miRNA but also as a tumor suppressor miRNA. Thus, MiR-663 impairs the upregulation of miR-155 by inflammatory stimuli [47]. In addition, the expression of this microRNA is lost in certain cancers such as gastric or pancreatic cancer, and it induces mitotic catastrophe growth arrest when its expression is restored in these cells [48].

3. MicroRNAs as Oncogenes and Tumor-Suppressor Genes

miRNAs participate in many gene regulatory networks whose molecular malfunctions are associated with cancers [35, 41]. Depending on the effects of their downregulation or overexpression, miRNAs have been described either as oncogenic (onco-miRs) or tumor suppressors. Thus, the miR-17-92 cluster on chromosome 13, which contains six miRNAs (miR-17, -18a, -19a, -20a, -19b-1, and -92a-1), is amplified and overexpressed in B-cell lymphomas and solid tumors such as breast or small-cell lung cancers, where it may enhance oncogenesis by potentially targeting E2F1, p21/CDKN1A, and BCL2L11/BIM [49]. On the other hand, loss of function of miR-17-92 miRNAs might be advantageous for cancer cells in certain settings. Namely, loss of heterozygosity at the 13q31.3 locus has been observed in multiple tumor types, and a genome-wide analysis of copy number alterations in cancer revealed that the miR-17-92 cluster was deleted in 16.5% of ovarian cancers, 21.9% of breast cancers, and 20% of melanomas [50]. In contrast, the twelve members of the human let-7 gene family are frequently downregulated in cancers like lung, colon, or other solid tumors [34, 35]s and are, therefore,s considered as tumor-suppressor miRNAs in these types of cancers. In particular, let-7 miRNAs target oncogenes of the Ras family [51] and c-Myc, and their expression in colon tumors results in reduced levels of both Ras and c-Myc [52]. miR-21 is overexpressed in several cancers, including colorectal carcinomas (CRCs), gliomas, as well as breast, gastric, prostate, pancreas, lung, thyroid, and cervical cancers [53, 54]. miR-21 has been shown to function as an onco-miR, due to its targeting of transcripts encoding key regulators of cell proliferation and apoptosis such as PTEN and PDCD4 [53]. Beside miR-21, several miRNAs are overexpressed in CRCs, including miR-17, miR-25, miR-26a, and miR-181a [54, 55].

In human, the levels of both miR-155 and BIC transcripts (that is, miR-155 primary RNAs) are elevated in diffuse large B-cell lymphoma (DLBCL), Hodgkins lymphoma, and primary mediastinal B-cell lymphoma [40]. In contrast, a very weak expression of miR-155 is found in most non-Hodgkins lymphoma subtypes, including Burkitt lymphoma. In addition, high levels of BIC and miR-155 expression were reported in B-cell chronic lymphocytic leukemia (B-CLL) and in B-CLL proliferation centers [56]. Furthermore, miR-155 was also upregulated in a subset of patients with acute myelomonocytic leukemia and acute monocytic leukemia. Accordingly, transgenic mice whose B cells overexpress miR-155 developed polyclonal preleukemic pre-B-cell proliferation followed by B-cell malignancy [40]. On the other hand, it was reported that BIC cooperates with c-Myc in avian lymphomagenesis and erythroleukemogenesis [57]. Beside liquid malignancies, high levels of miR-155 expression were found in solid tumors such as breast, colon, and lung cancers [40]. miR-155 was recently shown to induce a mutator phenotype by targeting Wee-1, a kinase regulating G₂/M phase transition during the cell cycle [58]. Furthermore, it was shown that miR-155 increases genomic instability by targeting transcripts encoding components of the DNA mismatch repair machinery [59]. As a consequence, the simultaneous miR-155-steered suppression of a number of tumor suppressor genes combined with a mutator phenotype might allow the shortening of steps required for tumorogenesis, and might also explain how chronic inflammation associated with high levels of miR-155 induces cancer.

Finally, miRNAs have been implicated in metastasis. For example, it has been established that the downregulation of both miR-103-1 and miR-103-2 miRNAs induces epithelial-to-mesenchymal transition by targeting Dicer1 transcripts [60]. Furthermore, several miRNAs, including miR-21, have been shown to activate metastasis by acting on multiple signaling pathways and targeting various proteins that are involved in this process. Thus, in breast cancer, which represents the most common malignancy among women in the world, miRNAs such as miR-9, miR-10b, miR-21, miR-103/107, miR-132, miR-373, and miR-520 stimulate metastasis, while miR-7, miR-30, miR-31, miR-126, miR-145, miR-146, miR-200, miR-205, miR-335, miR-661, and miRNAs of the let-7 families in contrast impair the different steps of metastatic process, from epithelial-to-mesenchymal transition to local invasion to colonisation and angiogenesis [61].

Numerous reports have provided strong evidence that all of the above miRNAs potentially target a myriad of transcripts including those encoding transcription factors, cytokines, enzymes and kinases, implicated in both cancer and inflammation.

4. Anti-Inflammatory and Antitumor Properties of Resveratrol

Resveratrol (trans-3,4′,5-trihydroxystilbene) is a natural polyphenolic, nonflavonoid antioxidant found in grapes and other berries, produced by plants in response to infection by the pathogen Botrytis cinerea [62]. Recent studies have documented that resveratrol has various health benefits, such as cardiovascular- and cancer-preventive properties [63–65], and this compound is currently at the stage of preclinical studies for human cancer prevention [66, 67]. Resveratrol was first shown to inhibit both tumor promotion and tumor progression in a mouse skin cancer model [68]. Resveratrol is also tested for preventing and/or treating obesity and diabetes [69, 70]. Fortunately, resveratrol toxicity is minimal, and even proliferating tissues such as bone marrow or intestinal tract are not adversely affected [71].

Resveratrol exerts its effects at multiple levels. Both its m-hydroxyquinone and 4-hydroxystyryl moieties have been shown to be important for the determination of resveratrol inhibitory properties toward various enzymes. This include lipoxygenases and cyclooxygenases that synthesize proinflammatory mediators from arachidonic acid, protein kinases such as PKCs and PKD, and receptor tyrosine kinases, lipid kinases, as well as IKKα, an activator of NF-κB pathway, which establishes a strong link between inflammation and tumorigenesis [72]. Also, resveratrol inhibition of P450/CYP19A1/Aromatase, by limiting the amount of available estrogens and consequently the activity of estrogen receptors, has been proposed to contribute to the protection against several types of cancer, including breast cancer [72, 73]. Of note, resveratrol also inhibits the formation of estrogen-DNA adducts, which are elevated in women at high risk for breast cancer [74].

Resveratrol in addition regulates apoptosis and cell proliferation. It induces growth arrest followed by apoptotic cell death and interferes with cell survival by upregulating the expression of proapoptotic genes while simultaneously downregulating the expression of antiapoptotic genes [75]. Resveratrol induces the redistribution of CD95 and other death receptors in lipid rafts, thus contributing to their sensitization to death receptor agonists [75]. It also causes growth arrest at G1 and G1/S phases of cell cycle by inducing the expression of CDK inhibitors p21/CDKN1A and p27/CDKN1B [63]. In addition, resveratrol directly inhibits DNA synthesis by diminishing ribonucleotide reductase and DNA polymerase [72, 76, 77]. Altogether, antiproliferative activities of resveratrol involve the differential regulation of multiple cell-cycle targets in a cell-type-dependent manner [72, 75].

One of the possible mechanisms for resveratrol protective activities is by downregulation of the inflammatory responses [78]. That includes the inhibition of synthesis and release of proinflammatory mediators, modifications of eicosanoid synthesis, or inhibiting the enzymes, such as cyclooxygenase-1 (COX-1/PTGS1) or -2 (COX-2/PTGS2), which are responsible for the synthesis of proinflammatory mediators, through the inhibitory effect of resveratrol on transcription factors like NF-κB or activator protein-1 (AP-1) [78, 79]. Of note, constitutive COX-2 expression generally predicts aggressiveness of tumors, therefore, the use of nonsteroidal anti-inflammatory drugs that inhibit COX-2 in cancer treatment. However, cytoplasmic COX-2 can relocalize in the nucleus. This nuclear relocalization of COX-2 is induced by resveratrol, and exposure of resveratrol-treated cells to a specific COX-2 inhibitor blocked resveratrol-induced apoptosis, indicating that COX-2 displays proapoptotic activity in the nucleus, which may be associated with the generation of complexes of COX-2 and ERK1/2 mitogen-activated protein kinases. In mouse macrophages, resveratrol also displays antioxidant activity, decreasing the production of reactive oxygen species and reactive nitrogen species and inhibiting nitric oxygen synthetase (NOS)-2 and COX-2 synthesis as well as prostaglandin E2 production [80].

Furthermore, in 3T3-L1 adipocytes, resveratrol inhibits the production of the TNF-induced monocyte chemoattractant protein (MCP)-1/CCL2. MCP-1 plays an essential role in the early events during macrophage infiltration into adipose-tissue, which results in chronic low-grade inflammation, a key feature of obesity type 2 diabetes characterized by adipose tissue macrophage infiltration and abnormal cytokine production [81]. Finally, it is also well established that some anti-inflammatory effects of resveratrol arise from its capability to upregulate histone deacetylase sirtuin 1 (SIRT1) activity, that also presents antitumor and anti-inflammatory capabilities [82]. Altogether, it is clear that the key antitumor properties of resveratrol [77–82] are linked to its anti-inflammatory effects.

The fact that resveratrol targets, directly or indirectly, so many different factors, exerts such a wide influence on cell homeostasis, and provides such a range of health benefits, suggested that some of its effects should arise from its capability to modulate the activity of global regulators. Furthermore, the ability of each miRNA to potentially regulate the levels and, therefore, the activity, of tens to hundreds of target genes, strongly suggested that resveratrol should be able to modify the composition of miRNA populations. Indeed, it has recently been shown that resveratrol decreases the levels of several proinflammatory and/or oncogenic miRNAs and upregulates miRNAs with anti-inflammatory and/or antitumor potentials [47, 83].

5. MiR-663 as a Mediator of Resveratrol Anti-Inflammatory Activity

Affymetrix microarrays and RNase-protection assays showed that resveratrol treatment of human THP-1 monocytic cells upregulated the expression of LOC284801 transcripts, that contain the sequence of pre-miR-663 and thus represent miR-663 primary transcripts. MiRNA microarrays and RNase-protection assays accordingly confirmed these data [47]. Interestingly, in silico analysis using TargetScan (http://www.targetscan.org/) suggested that miR-663 may potentially target transcripts encoding factors implicated in (i) the mounting of the immune response, especially JunB, JunD, and FosB, which encode AP-1 factors known to activate many cytokine genes in partnership with NFAT factors [84], (ii) TLR signaling, such as the kinases RIPK1 and IRAK2, and (iii) the differentiation of monocytes, Th1 lymphocytes, and granulocytes.

An antisense miR-663 inhibitory RNA (663-I) proved capable of increasing global AP-1 activity in unchallenged THP-1 cells, showing that miR-663 indeed target transcripts encoding AP-1 factors in these cells. These effects were in particular directed toward JunB and JunD transcripts [47]. In agreement with previous results [79], resveratrol blocked the surge of AP-1 activity that occurs following LPS challenge due to the fact that JunB transcripts peak within the first hour, leading to the accumulation of JunB in the next few hours [85]. This inhibitory effect of resveratrol on AP-1 activity was partly impaired by 663-I, indicating that it arises at least in part from the upregulation of miR-663 by resveratrol [47]. Western blots showed that resveratrol impaired JunB neosynthesis, while still allowing the phosphorylation, that is, the activation of JunB following LPS treatment to take place, at least to a certain extent. Given that AP-1 factors include c-Jun, JunB, JunD, FosB, Fra-1, and Fra-2, as well as Jun dimerization partners JDP1 and JDP2 or the closely related ATF2, LRF1/ATF3, and B-ATF, so that potentially about 18 different dimeric combinations may be formed, the capability of resveratrol to specifically target a subset of AP-1 dimers through the upregulation of miR-663 might have profound effects on the levels of the transcriptional activity of promoters to whom different AP-1 factors can compete for binding. Due to the many roles of AP-1 factors both in inflammation and cancer [86, 87], the specific targeting of genes encoding a subset of AP-1 factors, by changing the composition of AP-1 dimers on key promoters, may possibly explain some of the multiple anti-inflammatory and anticancer properties of resveratrol.

Of note, miR-155 had been shown to be under AP-1 activity in activated B cells [88]. Accordingly, miR-663 reduced the upregulation of miR-155 by LPS [42], which may be due to miR-663 targeting of transcripts encoding JunB and JunD and also possibly FosB and KSRP, an RNA binding protein implicated in the LPS-induced miR-155 maturation from its primary transcripts BIC [89]. This is of primary importance, for miR-155 upregulation is the hallmark of inflammatory response following LPS treatment of macrophages/monocytes [42]. Resveratrol also dramatically impaired the upregulation of miR-155 by LPS, an effect partly inhibited by 663-I [47]. Altogether, these results indicate that the anti-inflammatory properties of resveratrol arise, at least in part, from its upregulation of miR-663 and its downregulating effects on miR-155 and that miR-663 might possibly qualify as an anti-inflammatory miRNA.

6. MicroRNAs as Mediators of Resveratrol Anticancer Effects

The results reported here above also suggested that, due to its targeting of AP-1 factors, known to play a role in tumorigenesis and cell invasion [86, 87] and due to its downregulation of miR-155, whose levels increase in solid as well as in liquid tumors [40], miR-663 may also possibly provide resveratrol with some of its anticancer properties. Namely, miR-663 was found to be downregulated in hormone refractory prostate cancer cells, along with miR-146a and miR-146b [90], further supporting the hypothesis that this miRNA is a tumor-suppressor gene whose one of the function is to keep low the expression level of oncogenic miR-155 [47, 48].

CRC is the third most common malignancy and the fourth biggest cause of cancer mortality worldwide [91, 92]. Despite the increased use of screening strategies such as fecal occult blood testing, sigmoidoscopy, and colonoscopy, more than one-third of patients with colorectal cancer will ultimately develop metastatic disease [92]. On the other hand, the TGFβ signaling pathway is one of the most commonly altered cellular signaling pathways in human cancers [93]. Among the three TGFβ isoforms expressed in mammalian epithelia (TGFβ1, TGFβ2, and TGFβ3), TGFβ1 is the most abundant and ubiquitously expressed one. TGFβ signaling is initiated by the binding of TGFβ ligands to type II receptors (TGFβR2). Once bound by TGFβ, TGFβR2 recruits, phosphorylates, and thus activates the type I TGFβ receptor (TGFβR1). TGFβR1 then phosphorylates two transcriptional regulators, namely, SMAD2 and SMAD3, which subsequently bind to SMAD4. This results in the nuclear translocation of SMAD complexes, allowing SMADs to interact with transcription factors controlling the expression of a multitude of TGFβ responsive genes [94]. The expression of TGFβ1 in both tumor and plasma was found to be significantly higher in patients with metastatic colorectal cancer, and increasing colorectal tumor stage was correlated with higher TGFβ1 expression in tumor tissues [95].

miRNA microarrays recently showed that resveratrol treatment of SW480 human colon cancer cells significantly increased the levels of 22 miRNAs while decreasing those of 26 others [83]. Among the miRNAs downregulated by resveratrol, miR-17, miR-21, miR-25, miR-92a-2, miR-103-1 and miR-103-2 have been shown to behave as onco-miRNAs, at least in certain contexts. Thus, genomic amplification and overexpression of miR-17-92 miRNAs is found in B-cell lymphomas as well as in breast and lung cancers [34, 54]. MiR-21 is overexpressed in several cancers, including CRCs, gliomas, as well as breast, gastric, prostate, pancreas, lung, thyroid, and cervical cancers [53–55]. MiR-17, miR-25, miR-26-a, and miR-181a are also overexpressed in CRCs [34, 54]. In addition, several miRNAs, including miR-21, have been shown to activate metastasis by acting on multiple signaling pathways and targeting various proteins that are key players in this process [53]. Furthermore, the lower metastatic propensity of SW480 cells as compared with SW620 human colon cancer cells, both derived from the primary tumor and a metastasis of the same patient, respectively [96], was associated with a lower level of expression of miR-103-1 and miR-103-2, two miRNAs that induce epithelial-to-mesenchymal transition by targeting Dicer1 transcripts [60].

In silico analysis using TargetScan showed that miRNAs downregulated by resveratrol in SW480 cells potentially target transcripts encoding known tumor suppressor factors, such as the two antiproliferation factors PDCD4 and PTEN, the components of the mismatch repair machinery MLH3, MSH2 and MSH3, DICER1, the RNase III producing mature miRNAs from their immediate precursors in the cytoplasm, and several effectors and regulators of the TGFβ signaling pathway [83]. Indeed, resveratrol treatment of SW480 cells lead to a greater accumulation of TGFβR1, TGFβR2, PDCD4, PTEN, and E-CADHERIN (a component of adherens junctions implicated in the maintenance of epithelial phenotype) [83]. Of note, among miRNAs upregulated by resveratrol, miR-663 was the only one to target TGFβ1 transcripts. Luciferase assays and Western blots showed that resveratrol downregulated TGFβ1 in both a miR-663-dependent and a miR-663-independent manner [83]. Resveratrol treatment also decreased the transcriptional activity of SMADs under TGFβ1 signaling, an effect seemingly independent of miR-663 [83].

Interestingly, it has been recently shown that GAM/ZNF512B, a vertebrate-specific developmental regulator first described in chicken [97], impairs the upregulation of miRNAs of the miR-17-92 cluster by TGFβ1 and that TGFβ1 in turn downregulates GAM, at least in part through the upregulation of miR-17-92 miRNAs [98]. The facts that GAM transcripts contain three consensus target sites for miR-663 and that GAM is sensible to resveratrol treatment (Tili et al., unpublished results) raises the question of the possible existence of a gene regulatory network that would allow miR-663 to impair GAM repressing activity on TGFβ1 signaling pathway when TGFβ1 works as a tumor suppressor, that is, at the early stages of tumorigenesis but not any more when this pathway starts to favor tumorigenesis and metastasis, that is, on advanced stages of cancers.

It is important to emphasize that TGFβ1 has been shown to enhance the maturation of oncogenic miR-21 through the binding of SMAD3 to miR-21 primary RNAs [99] and also to increase the expression of miR-155, which is under the control of TGFβ/SMAD activity [100]. Thus, by targeting AP-1 factors as well as TGFβ1 and possibly SMAD3, miR-663 might inhibit two of the pathways that upregulate miR-155 expression.

The TGFβ signaling pathway present multiple levels of regulation: sequestration of ligands into inactive precursor forms, ligand traps, decoy receptors, and inhibitory SMADs, not to mention the existence of SMAD-independent pathways and their interactions with many other critical signaling pathways which also proved to play a role in cancer. It is thus not surprising that the short (307-nt long) 3′-UTR of TGFβ1 transcripts contains a potential consensus target site for 28 miRNAs only. Of note, TGFβ1 3′-UTR contains two target sites for two of these miRNAs and only one target site for 25 of the others. Therefore, the fact that miR-663 may potentially target 5 different sites in TGFβ1 3′-UTR suggests that this miRNA could represent a critical TGFβ1 regulator which may possibly be called upon action in emergency situations such as those when cells begin to proliferate anarchically or when a stronger immune response is required. The multiplicity of miR-663 targets sites in TGFβ1 3′-UTR further suggests that the effects of this miRNA might be both dose- and context-dependent, so that resveratrol effects on TGFβ1 signaling pathway might well be also context-dependent. Finally, it is probable that, depending on the cell context, resveratrol might either increase the level of TGFβ signaling—by inhibiting miRNAs targeting its main effectors—when it is beneficial to the organism, that is, when it works to maintain the integrity of epithelia and impair cell proliferation, or in contrast decrease TGFβ1 signaling—by decreasing its production through the upregulation of miR-663—when TGFβ1 starts to favor epithelial-to-mesenchymal transition and metastasis. For example, the targeting of both TGFβ1 and SMAD3 transcripts might possibly allow resveratrol to impair TGFβ1-induced SMAD3-dependent promotion of cell motility and invasiveness in advanced stages of gastric cancer [101, 102] or when SMAD2 and SMAD3 phosphorylated at both linker and COOH-terminal regions transmit malignant TGFβ1 signal in later stages of human CRC [103].

7. Conclusions

It is notable that striking phenotypes are often driven through small changes in the cellular concentration of key factors. For example, in the B-cell compartment, miR-150 curtails the activity of c-Myb transcription factor in a dose-dependent fashion over a narrow range of miRNA and c-Myb concentrations [104]. Thus, even slight effects of resveratrol on a handful of key miRNAs might well prove to be critical to its anti-inflammatory, anticancer and antimetastatic properties. In addition, the fact that miR-663, miR-21, miR-155, and TGFβ1 have all been implicated in the regulation of cell proliferation, tumor apparition and development, metastasis formation, and innate immunity, strongly suggests that the capability of resveratrol to behave at the same time as an antitumor, antimetastatic, antiproliferation and anti-inflammatory agent most probably arises from its effects on the expression of a small set of critical endogenous miRNAs having the abilities to impact the cell proteome globally.

Finally, miRNAs have the promise to become biomarkers for different stages of cancer, both for diagnosis and prognosis. Furthermore, the discovery that resveratrol can modulate the levels of miRNAs targeting proinflammatory and/or protumor factors opens the possibility to optimize resveratrol treatments by manipulating in parallel the levels of expression of a few critical miRNAs. For example, from the experiments reported here above, it starts to become clear that the use of resveratrol would be especially beneficiary in the type of cancers where the TGFβ pathway is implicated. Of course, resveratrol use would have to be carefully correlated with the stages of cancers, knowing that TGFβ can have two faces, that is, anti- and prometastatic.

As a last remark, it should be noted that while resveratrol antitumor potential has been linked with data primarily from human cell culture systems, evidence that resveratrol can inhibit carcinogenesis in several organ sites emerged from results of cancer prevention and therapy studies in laboratory animal models [68]. Given that miR-663 was only found in primates, the reports by Tili et al. [47, 83] come as a warning that studies in animal may not always allow to predict accurately the molecular effects of resveratrol in human, especially when it comes to miRNAs.

References

R. Medzhitov, “Origin and physiological roles of inflammation,” Nature, vol. 454, no. 7203, pp. 428–435, 2008.
View at: Publisher Site | Google Scholar
C. Gerard and B. J. Rollins, “Chemokines and disease,” Nature Immunology, vol. 2, no. 2, pp. 108–115, 2001.
View at: Publisher Site | Google Scholar
I. F. Charo and R. M. Ransohoff, “The many roles of chemokines and chemokine receptors in inflammation,” The New England Journal of Medicine, vol. 354, no. 6, pp. 610–621, 2006.
View at: Publisher Site | Google Scholar
A. Mantovani, B. Savino, M. Locati, L. Zammataro, P. Allavena, and R. Bonecchi, “The chemokine system in cancer biology and therapy,” Cytokine and Growth Factor Reviews, vol. 21, no. 1, pp. 27–39, 2010.
View at: Publisher Site | Google Scholar
S. P. Hussain and C. C. Harris, “Inflammation and cancer: an ancient link with novel potentials,” International Journal of Cancer, vol. 121, no. 11, pp. 2373–2380, 2007.
View at: Publisher Site | Google Scholar
A. Mantovani, P. Allavena, A. Sica, and F. Balkwill, “Cancer-related inflammation,” Nature, vol. 454, no. 7203, pp. 436–444, 2008.
View at: Publisher Site | Google Scholar
F. Colotta, P. Allavena, A. Sica, C. Garlanda, and A. Mantovani, “Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability,” Carcinogenesis, vol. 30, no. 7, pp. 1073–1082, 2009.
View at: Publisher Site | Google Scholar
S. Rakoff-Nahoum and R. Medzhitov, “Toll-like receptors and cancer,” Nature Reviews Cancer, vol. 9, no. 1, pp. 57–63, 2009.
View at: Publisher Site | Google Scholar
L. Sfondrini, A. Rossini, D. Besusso et al., “Antitumor activity of the TLR-5 ligand flagellin in mouse models of cancer,” Journal of Immunology, vol. 176, no. 11, pp. 6624–6630, 2006.
View at: Google Scholar
G. P. Pidgeon, J. H. Harmey, E. Kay, M. da Costa, H. P. Redmond, and D. J. Bouchier-Hayes, “The role of endotoxin/lipopolysaccharide in surgically induced tumour growth in a murine model of metastatic disease,” British Journal of Cancer, vol. 81, no. 8, pp. 1311–1317, 1999.
View at: Google Scholar
J. H. Harmey, C. D. Bucana, W. Lu et al., “Lipopolysaccharide-induced metastatic growth is associated with increased angiogenesis, vascular permeability and tumor cell invasion,” International Journal of Cancer, vol. 101, no. 5, pp. 415–422, 2002.
View at: Publisher Site | Google Scholar
G. Jego, R. Bataille, A. Geffroy-Luseau, G. Descamps, and C. Pellat-Deceunynck, “Pathogen-associated molecular patterns are growth and survival factors for human myeloma cells through Toll-like receptors,” Leukemia, vol. 20, no. 6, pp. 1130–1137, 2006.
View at: Publisher Site | Google Scholar
J. Bohnhorst, T. Rasmussen, S. H. Moen et al., “Toll-like receptors mediate proliferation and survival of multiple myeloma cells,” Leukemia, vol. 20, no. 6, pp. 1138–1144, 2006.
View at: Publisher Site | Google Scholar
B. Huang, J. Zhao, S. Shen et al., “Listeria monocytogenes promotes tumor growth via tumor cell toll-like receptor 2 signaling,” Cancer Research, vol. 67, no. 9, pp. 4346–4352, 2007.
View at: Publisher Site | Google Scholar
B. Huang, J. Zhao, H. Li et al., “Toll-like receptors on tumor cells facilitate evasion of immune surveillance,” Cancer Research, vol. 65, no. 12, pp. 5009–5014, 2005.
View at: Publisher Site | Google Scholar
F. Balkwill and A. Mantovani, “Inflammation and cancer: back to Virchow?” The Lancet, vol. 357, no. 9255, pp. 539–545, 2001.
View at: Publisher Site | Google Scholar
L. M. Coussens and Z. Werb, “Inflammation and cancer,” Nature, vol. 420, no. 6917, pp. 860–867, 2002.
View at: Publisher Site | Google Scholar
M. Ono, “Molecular links between tumor angiogenesis and inflammation: inflammatory stimuli of macrophages and cancer cells as targets for therapeutic strategy,” Cancer Science, vol. 99, no. 8, pp. 1501–1506, 2008.
View at: Publisher Site | Google Scholar
J. W. Pollard, “Tumour-educated macrophages promote tumour progression and metastasis,” Nature Reviews Cancer, vol. 4, no. 1, pp. 71–78, 2004.
View at: Google Scholar
A. Yoshimura, “Signal transduction of inflammatory cytokines and tumor development,” Cancer Science, vol. 97, no. 6, pp. 439–447, 2006.
View at: Publisher Site | Google Scholar
A. Sica and V. Bronte, “Altered macrophage differentiation and immune dysfunction in tumor development,” Journal of Clinical Investigation, vol. 117, no. 5, pp. 1155–1165, 2007.
View at: Publisher Site | Google Scholar
J. Condeelis and J. W. Pollard, “Macrophages: obligate partners for tumor cell migration, invasion, and metastasis,” Cell, vol. 124, no. 2, pp. 263–266, 2006.
View at: Publisher Site | Google Scholar
E. Y. Lin, A. V. Nguyen, R. G. Russell, and J. W. Pollard, “Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy,” Journal of Experimental Medicine, vol. 193, no. 6, pp. 727–740, 2001.
View at: Publisher Site | Google Scholar
B. Bierie and H. L. Moses, “Transforming growth factor beta (TGF-β) and inflammation in cancer,” Cytokine and Growth Factor Reviews, vol. 21, no. 1, pp. 49–59, 2010.
View at: Publisher Site | Google Scholar
M. O. Li, Y. Y. Wan, S. Sanjabi, A. K. L. Robertson, and R. A. Flavell, “Transforming growth factor-β regulation of immune responses,” Annual Review of Immunology, vol. 24, pp. 99–146, 2006.
View at: Publisher Site | Google Scholar
S. H. Wrzesinski, Y. Y. Wan, and R. A. Flavell, “Transforming growth factor-β and the immune response: implications for anticancer therapy,” Clinical Cancer Research, vol. 13, no. 18, pp. 5262–5270, 2007.
View at: Publisher Site | Google Scholar
J. Massagué, S. W. Blain, and R. S. Lo, “TGFβ signaling in growth control, cancer, and heritable disorders,” Cell, vol. 103, no. 2, pp. 295–309, 2000.
View at: Google Scholar
J. Massagué, “TGFβ in cancer,” Cell, vol. 134, no. 2, pp. 215–230, 2008.
View at: Publisher Site | Google Scholar
D. Padua and J. Massagué, “Roles of TGFβ in metastasis,” Cell Research, vol. 19, no. 1, pp. 89–102, 2009.
View at: Publisher Site | Google Scholar
M. Tian and W. P. Schiemann, “The TGFβ paradox in human cancer: an update,” Future Oncology, vol. 5, no. 2, pp. 259–271, 2009.
View at: Publisher Site | Google Scholar
V. Ambros, “The functions of animal microRNAs,” Nature, vol. 431, no. 7006, pp. 350–355, 2004.
View at: Publisher Site | Google Scholar
D. P. Bartel and C. Z. Chen, “Micromanagers of gene expression: the potentially widespread influence of metazoan microRNAs,” Nature Reviews Genetics, vol. 5, no. 5, pp. 396–400, 2004.
View at: Google Scholar
G. Stefani and F. J. Slack, “Small non-coding RNAs in animal development,” Nature Reviews Molecular Cell Biology, vol. 9, no. 3, pp. 219–230, 2008.
View at: Publisher Site | Google Scholar
E. Tili, J. J. Michaille, V. Gandhi, W. Plunkett, D. Sampath, and G. A. Calin, “MiRNAs and their potential for use against cancer and other diseases,” Future Oncology, vol. 3, no. 5, pp. 521–537, 2007.
View at: Publisher Site | Google Scholar
E. Tili, J. J. Michaille, S. Costinean, and C. M. Croce, “MicroRNAs, the immune system and rheumatic disease,” Nature Clinical Practice Rheumatology, vol. 4, no. 10, pp. 534–541, 2008.
View at: Publisher Site | Google Scholar
J. Winter, S. Jung, S. Keller, R. I. Gregory, and S. Diederichs, “Many roads to maturity: microRNA biogenesis pathways and their regulation,” Nature Cell Biology, vol. 11, no. 3, pp. 228–234, 2009.
View at: Publisher Site | Google Scholar
J. Tsang, J. Zhu, and A. van Oudenaarden, “MicroRNA-mediated feedback and feedforward loops are recurrent network motifs in mammals,” Molecular Cell, vol. 26, no. 5, pp. 753–767, 2007.
View at: Publisher Site | Google Scholar
E. Sonkoly and A. Pivarcsi, “Advances in microRNAs: implications for immunity and inflammatory diseases,” Journal of Cellular and Molecular Medicine, vol. 13, no. 1, pp. 24–38, 2009.
View at: Publisher Site | Google Scholar
M. Iborra, F. Bernuzzi, P. Invernizzi, and S. Danese, “MicroRNAs in autoimmunity and inflammatory bowel disease: crucial regulators in immune response,” Autoimmunity Reviews, 2010.
View at: Publisher Site | Google Scholar
E. Tili, C. M. Croce, and J. J. Michaille, “MiR-155: on the crosstalk between inflammation and cancer,” International Reviews of Immunology, vol. 28, no. 5, pp. 264–284, 2009.
View at: Google Scholar
E. Tili, J. J. Michaille, and G. A. Calin, “Expression and function of micro-RNAs in immune cells during normal or disease state,” International Journal of Medical Sciences, vol. 5, no. 2, pp. 73–79, 2008.
View at: Google Scholar
E. Tili, J. J. Michaille, A. Cimino et al., “Modulation of miR-155 and miR-125b levels following lipopolysaccharide/TNF-α stimulation and their possible roles in regulating the response to endotoxin shock,” Journal of Immunology, vol. 179, no. 8, pp. 5082–5089, 2007.
View at: Google Scholar
E. Sonkoly, T. Wei, P. C. Janson et al., “MicroRNAs: novel regulators involved in the pathogenesis of psoriasis?” PLoS One, vol. 2, no. 7, p. e610, 2007.
View at: Google Scholar
F. Wu, M. Zikusoka, A. Trindade et al., “MicroRNAs are differentially expressed in ulcerative colitis and alter expression of macrophage inflammatory peptide-2α,” Gastroenterology, vol. 135, no. 5, article e24, pp. 1624–1635, 2008.
View at: Publisher Site | Google Scholar
T. X. Lu, A. Munitz, and M. E. Rothenberg, “MicroRNA-21 is up-regulated in allergic airway inflammation and regulates IL-12p35 expression,” Journal of Immunology, vol. 182, no. 8, pp. 4994–5002, 2009.
View at: Publisher Site | Google Scholar
H. Wu, J. R. Neilson, P. Kumar et al., “MiRNA profiling of naïve, effector and memory CD8 T cells,” PLoS One, vol. 2, no. 10, Article ID e1020, 2007.
View at: Publisher Site | Google Scholar
E. Tili, J. J. Michaille, B. Adair et al., “Resveratrol decreases the levels of miR-155 by upregulating miR-663, a microRNA targeting JunB and JunD,” Carcinogenesis, vol. 31, no. 9, pp. 1561–1566, 2010.
View at: Publisher Site | Google Scholar
J. Pan, H. Hu, Z. Zhou et al., “Tumor-suppressive mir-663 gene induces mitotic catastrophe growth arrest in human gastric cancer cells,” Oncology Reports, vol. 24, no. 1, pp. 105–112, 2010.
View at: Publisher Site | Google Scholar
J. T. Mendell, “MiRiad roles for the miR-17-92 cluster in development and disease,” Cell, vol. 133, no. 2, pp. 217–222, 2008.
View at: Publisher Site | Google Scholar
L. Zhang, J. Huang, N. Yang et al., “MicroRNAs exhibit high frequency genomic alterations in human cancer,” Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 24, pp. 9136–9141, 2006.
View at: Publisher Site | Google Scholar
S. M. Johnson, H. Grosshans, J. Shingara et al., “RAS is regulated by the let-7 microRNA family,” Cell, vol. 120, no. 5, pp. 635–647, 2005.
View at: Publisher Site | Google Scholar
Y. Akao, Y. Nakagawa, and T. Naoe, “Let-7 microRNA functions as a potential growth suppressor in human colon cancer cells,” Biological and Pharmaceutical Bulletin, vol. 29, no. 5, pp. 903–906, 2006.
View at: Publisher Site | Google Scholar
A. M. Krichevsky and G. Gabriely, “MiR-21: a small multi-faceted RNA,” Journal of Cellular and Molecular Medicine, vol. 13, no. 1, pp. 39–53, 2009.
View at: Publisher Site | Google Scholar
S. Volinia, G. A. Calin, C. G. Liu et al., “A microRNA expression signature of human solid tumors defines cancer gene targets,” Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 7, pp. 2257–2261, 2006.
View at: Publisher Site | Google Scholar
O. Slaby, M. Svoboda, P. Fabian et al., “Altered expression of miR-21, miR-31, miR-143 and miR-145 is related to clinicopathologic features of colorectal cancer,” Oncology, vol. 72, no. 5-6, pp. 397–402, 2007.
View at: Publisher Site | Google Scholar
G. A. Calin, M. Ferracin, A. Cimmino et al., “A microRNA signature associated with prognosis and progression in chronic lymphocytic leukemia,” The New England Journal of Medicine, vol. 353, no. 17, pp. 1793–1801, 2005.
View at: Publisher Site | Google Scholar
W. Tam, S. H. Hughes, W. S. Hayward, and P. Besmer, “Avian bic, a gene isolated from a common retroviral site in avian leukosis virus-induced lymphomas that encodes a noncoding RNA, cooperates with c-myc in lymphomagenesis and erythroleukemogenesis,” Journal of Virology, vol. 76, no. 9, pp. 4275–4286, 2002.
View at: Publisher Site | Google Scholar
E. Tili, J. J. Michaille, D. Wernicke et al., “Mutator activity induced by microRNA-155 (miR-155) links inflammation and cancer,” Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 12, pp. 4908–4913, 2011.
View at: Publisher Site | Google Scholar
N. Valeri, P. Gasparini, M. Fabbri et al., “Modulation of mismatch repair and genomic stability by miR-155,” Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 15, pp. 6982–6987, 2011.
View at: Publisher Site | Google Scholar
G. Martello, A. Rosato, F. Ferrari et al., “A microRNA targeting dicer for metastasis control,” Cell, vol. 141, no. 7, pp. 1195–1207, 2010.
View at: Publisher Site | Google Scholar
M. Shi, D. Liu, H. Duan, B. Shen, and N. Guo, “Metastasis-related miRNAs, active players in breast cancer invasion, and metastasis,” Cancer and Metastasis Reviews, vol. 29, pp. 785–799, 2010.
View at: Publisher Site | Google Scholar
D. Delmas, A. Lançon, D. Colin, B. Jannin, and N. Latruffe, “Resveratrol as a chemopreventive agent: a promising molecule for fighting cancer,” Current Drug Targets, vol. 7, no. 4, pp. 423–442, 2006.
View at: Publisher Site | Google Scholar
S. Shankar, G. Singh, and R. K. Srivastava, “Chemoprevention by resveratrol: molecular mechanisms and therapeutic potential,” Frontiers in Bioscience, vol. 12, pp. 4839–4854, 2007.
View at: Publisher Site | Google Scholar
A. Csiszar, K. Smith, N. Labinskyy, Z. Orosz, A. Rivera, and Z. Ungvari, “Resveratrol attenuates TNF-α-induced activation of coronary arterial endothelial cells: role of NF-κB inhibition,” American Journal of Physiology—Heart and Circulatory Physiology, vol. 291, no. 4, pp. H1694–H1699, 2006.
View at: Publisher Site | Google Scholar
M. Athar, J. H. Back, L. Kopelovich, D. R. Bickers, and A. L. Kim, “Multiple molecular targets of resveratrol: anti-carcinogenic mechanisms,” Archives of Biochemistry and Biophysics, vol. 486, no. 2, pp. 95–102, 2009.
View at: Publisher Site | Google Scholar
A. Bishayee, “Cancer prevention and treatment with resveratrol: from rodent studies to clinical trials,” Cancer Prevention Research, vol. 2, no. 5, pp. 409–418, 2009.
View at: Publisher Site | Google Scholar
M. Athar, J. H. Back, X. Tang et al., “Resveratrol: a review of preclinical studies for human cancer prevention,” Toxicology and Applied Pharmacology, vol. 224, no. 3, pp. 274–283, 2007.
View at: Publisher Site | Google Scholar
M. Jang, L. Cai, G. O. Udeani et al., “Cancer chemopreventive activity of resveratrol, a natural product derived from grapes,” Science, vol. 275, no. 5297, pp. 218–220, 1997.
View at: Google Scholar
K. Szkudelska and T. Szkudelski, “Resveratrol, obesity and diabetes,” European Journal of Pharmacology, vol. 635, no. 1–3, pp. 1–8, 2010.
View at: Publisher Site | Google Scholar
T. E. Sonnett, T. L. Levien, B. J. Gates, J. D. Robinson, and R. K. Campbell, “Diabetes mellitus, inflammation, obesity: proposed treatment pathways for current and future therapies,” Annals of Pharmacotherapy, vol. 44, no. 4, pp. 701–711, 2010.
View at: Publisher Site | Google Scholar
J. A. Crowell, P. J. Korytko, R. L. Morrissey, T. D. Booth, and B. S. Levine, “Resveratrol-associated renal toxicity,” Toxicological Sciences, vol. 82, no. 2, pp. 614–619, 2004.
View at: Publisher Site | Google Scholar
L. Pirola and S. Fröjdö, “Resveratrol: one molecule, many targets,” IUBMB Life, vol. 60, no. 5, pp. 323–332, 2008.
View at: Publisher Site | Google Scholar
L. Le Corre, N. Chalabi, L. Delort, Y. J. Bignon, and D. J. Bernard-Gallon, “Resveratrol and breast cancer chemoprevention: molecular mechanisms,” Molecular Nutrition and Food Research, vol. 49, no. 5, pp. 462–471, 2005.
View at: Publisher Site | Google Scholar
E. L. Cavalieri and E. G. Rogan, “Depurinating estrogen-DNA adducts in the etiology and prevention of breast and other human cancers,” Future Oncology, vol. 6, no. 1, pp. 75–91, 2010.
View at: Publisher Site | Google Scholar
D. Delmas, C. Rébé, O. Micheau et al., “Redistribution of CD95, DR4 and DR5 in rafts accounts for the synergistic toxicity of resveratrol and death receptor ligands in colon carcinoma cells,” Oncogene, vol. 23, no. 55, pp. 8979–8986, 2004.
View at: Publisher Site | Google Scholar
M. Fontecave, M. Lepoivre, E. Elleingand, C. Gerez, and O. Guittet, “Resveratrol, a remarkable inhibitor of ribonucleotide reductase,” FEBS Letters, vol. 421, no. 3, pp. 277–279, 1998.
View at: Publisher Site | Google Scholar
N. J. Sun, S. H. Woo, J. M. Cassady, and R. M. Snapka, “DNA polymerase and topoisomerase II inhibitors from Psoralea corylifolia,” Journal of Natural Products, vol. 61, no. 3, pp. 362–366, 1998.
View at: Publisher Site | Google Scholar
S. Das and D. K. Das, “Anti-inflammatory responses of resveratrol,” Inflammation and Allergy—Drug Targets, vol. 6, no. 3, pp. 168–173, 2007.
View at: Publisher Site | Google Scholar
J. K. Kundu, Y. K. Shin, and Y. J. Surh, “Resveratrol modulates phorbol ester-induced pro-inflammatory signal transduction pathways in mouse skin in vivo: NF-κB and AP-1 as prime targets,” Biochemical Pharmacology, vol. 72, no. 11, pp. 1506–1515, 2006.
View at: Publisher Site | Google Scholar
J. Leiro, E. Álvarez, J. A. Arranz, R. Laguna, E. Uriarte, and F. Orallo, “Effects of cis-resveratrol on inflammatory murine macrophages: antioxidant activity and down-regulation of inflammatory genes,” Journal of Leukocyte Biology, vol. 75, no. 6, pp. 1156–1165, 2004.
View at: Publisher Site | Google Scholar
J. Zhu, W. Yong, X. Wu et al., “Anti-inflammatory effect of resveratrol on TNF-α-induced MCP-1 expression in adipocytes,” Biochemical and Biophysical Research Communications, vol. 369, no. 2, pp. 471–477, 2008.
View at: Publisher Site | Google Scholar
S. Chung, H. Yao, S. Caito, J. W. Hwang, G. Arunachalam, and I. Rahman, “Regulation of SIRT1 in cellular functions: role of polyphenols,” Archives of Biochemistry and Biophysics, vol. 501, no. 1, pp. 79–90, 2010.
View at: Publisher Site | Google Scholar
E. Tili, J. J. Michaille, H. Alder et al., “Resveratrol modulates the levels of microRNAs targeting genes encoding tumor-suppressors and effectors of TGFβ signaling pathway in SW480 cells,” Biochemical Pharmacology, vol. 80, no. 12, pp. 2057–2065, 2010.
View at: Publisher Site | Google Scholar
F. Macián, C. López-Rodríguez, and A. Rao, “Partners in transcription: NFAT and AP-1,” Oncogene, vol. 20, no. 19, pp. 2476–2489, 2001.
View at: Publisher Site | Google Scholar
M. Fujihara, M. Muroi, Y. Muroi, N. Ito, and T. Suzuki, “Mechanism of lipopolysaccharide-triggered junB activation in a mouse macrophage-like cell line (J774),” Journal of Biological Chemistry, vol. 268, no. 20, pp. 14896–14905, 1993.
View at: Google Scholar
B. W. Ozanne, H. J. Spence, L. C. McGarry, and R. F. Hennigan, “Transcription factors control invasion: AP-1 the first among equals,” Oncogene, vol. 26, no. 1, pp. 1–10, 2007.
View at: Publisher Site | Google Scholar
P. Verde, L. Casalino, F. Talotta, M. Yaniv, and J. B. Weitzman, “Deciphering AP-1 function in tumorigenesis: fra-ternizing on target promoters,” Cell Cycle, vol. 6, no. 21, pp. 2632–2639, 2007.
View at: Google Scholar
Q. Yin, X. Wang, J. McBride, C. Fewell, and E. Flemington, “B-cell receptor activation induces BIC/miR-155 expression through a conserved AP-1 element,” Journal of Biological Chemistry, vol. 283, no. 5, pp. 2654–2662, 2008.
View at: Publisher Site | Google Scholar
T. Ruggiero, M. Trabucchi, F. de Santa et al., “LPS induces KH-type splicing regulatory protein-dependent processing of microRNA-155 precursors in macrophages,” Federation of American Societies for Experimental Biology Journal, vol. 23, no. 9, pp. 2898–2908, 2009.
View at: Publisher Site | Google Scholar
S. L. Lin, A. Chiang, D. Chang, and S. Y. Ying, “Loss of mir-146a function in hormone-refractory prostate cancer,” RNA, vol. 14, no. 3, pp. 417–424, 2008.
View at: Publisher Site | Google Scholar
A. Tenesa and M. G. Dunlop, “New insights into the aetiology of colorectal cancer from genome-wide association studies,” Nature Reviews Genetics, vol. 10, no. 6, pp. 353–358, 2009.
View at: Publisher Site | Google Scholar
A. Jemal, R. Siegel, E. Ward et al., “Cancer statistics, 2006,” A Cancer Journal for Clinicians, vol. 56, no. 2, pp. 106–130, 2006.
View at: Publisher Site | Google Scholar
R. J. Akhurst, “TGFβ signaling in health and disease,” Nature Genetics, vol. 36, no. 8, pp. 790–792, 2004.
View at: Publisher Site | Google Scholar
R. L. Elliott and G. C. Blobe, “Role of transforming growth factor beta in human cancer,” Journal of Clinical Oncology, vol. 23, no. 9, pp. 2078–2093, 2005.
View at: Publisher Site | Google Scholar
M. Langenskiöld, L. Holmdahl, P. Falk, E. V. A. Angenete, and M. L. Ivarsson, “Increased TGF-beta1 protein expression in patients with advanced colorectal cancer,” Journal of Surgical Oncology, vol. 97, no. 5, pp. 409–415, 2008.
View at: Publisher Site | Google Scholar
A. Leibovitz, J. C. Stinson, and W. B. McCombs III, “Classification of human colorectal adenocarcinoma cell lines,” Cancer Research, vol. 36, no. 12, pp. 4562–4569, 1976.
View at: Google Scholar
J. J. Michaille, E. Tili, G. A. Calin, J. Garin, M. Louwagie, and C. M. Croce, “Cloning and characterization of cDNAs expressed during chick development and encoding different isoforms of a putative zinc finger transcriptional regulator,” Biochimie, vol. 87, no. 11, pp. 939–949, 2005.
View at: Publisher Site | Google Scholar
E. Tili, J. J. Michaille, C. G. Liu et al., “GAM/ZFp/ZNF512B is central to a gene sensor circuitry involving cell-cycle regulators, TGFβ effectors, Drosha and microRNAs with opposite oncogenic potentials,” Nucleic Acids Research, vol. 38, no. 21, pp. 7673–7688, 2010.
View at: Publisher Site | Google Scholar
B. N. Davis, A. C. Hilyard, G. Lagna, and A. Hata, “SMAD proteins control DROSHA-mediated microRNA maturation,” Nature, vol. 454, no. 7200, pp. 56–61, 2008.
View at: Publisher Site | Google Scholar
W. Kong, H. Yang, L. He et al., “MicroRNA-155 is regulated by the transforming growth factor β/Smad pathway and contributes to epithelial cell plasticity by targeting RhoA,” Molecular and Cellular Biology, vol. 28, no. 22, pp. 6773–6784, 2008.
View at: Publisher Site | Google Scholar
S. M. Wahl, J. Wen, and N. Moutsopoulos, “TGF-β: a mobile purveyor of immune privilege,” Immunological Reviews, vol. 213, no. 1, pp. 213–227, 2006.
View at: Publisher Site | Google Scholar
Y. A. Yoo, M. H. Kang, J. S. Kim, and S. C. Oh, “Sonic hedgehog signaling promotes motility and invasiveness of gastric cancer cells through TGF-β-mediated activation of the ALK5-Smad3 pathway,” Carcinogenesis, vol. 29, no. 3, pp. 480–490, 2008.
View at: Publisher Site | Google Scholar
K. Matsuzaki, C. Kitano, M. Murata et al., “Smad2 and Smad3 phosphorylated at both linker and COOH-terminal regions transmit malignant TGF-β signal in later stages of human colorectal cancer,” Cancer Research, vol. 69, no. 13, pp. 5321–5330, 2009.
View at: Publisher Site | Google Scholar
C. Xiao, D. P. Calado, G. Galler et al., “MiR-150 controls B cell differentiation by targeting the transcription factor c-Myb,” Cell, vol. 131, no. 1, pp. 146–159, 2007.
View at: Publisher Site | Google Scholar

Copyright

Copyright © 2011 Esmerina Tili and Jean-Jacques Michaille. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

PDF Download Citation

Download other formats

Order printed copies

Views

5540

Downloads

2361

Citations